INCFinder

GenBank ID	LC501656.1
Plasmid name	p23C152-3 (contig 1)
Classification	C1
Length	70 819 bp
GC content	51%
Organism	Escherichia coli 23-Ec-C-152
Curation	Manually annotated

Plasmid map

Notes

Incomplete plasmid sequence (contig1). The entire plasmid sequence may be assembled from the 4 contigs GenBank LC501656.1 - LC501659.1. RHS1, orf1832 and the empty site of I2 insertion are intact, the site of I1 insertion is missing.

Characteristic genes

Gene name	Length	Location	Length of alignment	Identity (%)	Coverage (%)	E-value
repA	1101	17282 - 18382 (-)	1101	100	100	0
RHS1	4254	40388 - 44641 (-)	4254	100	100	0

Antimicrobial resistance genes

Type match	Model name	Model type	Location	E-value	Identity
Perfect	QnrS1	protein homolog model	66672 - 67328(-)	6.836e-167	100 %
quinolone resistance protein (qnr) AMR Gene Family Qnr proteins are pentapeptide repeat proteins that mimic DNA and protect the cell from the activity of fluoroquinolone antibiotics ciprofloxacin Antibiotic Ciprofloxacin is a bacteriocidal fluoroquinolone. It blocks bacterial DNA replication by binding to the toposiomerase II or IV-DNA complex (or cleavable complex), thereby causing double-stranded breaks in the bacterial chromosome. levofloxacin Antibiotic Levofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class. Its main target is topoisomerase IV, inhibiting its function and disrupting DNA replication. moxifloxacin Antibiotic Moxifloxacin is a fourth generation synthetic fluoroquinolone chemotherapeutic agent, and has been shown to be significantly more active than levofloxacin (4 to 8 times more) against Streptococcus pneumoniae. It acts by inhibiting bacterial DNA topoisomerases. gatifloxacin Antibiotic Gatifloxacin is an 8-methoxy, 7-piperazinyl, 6-fluoroquinolone that can be taken orally or by intravenous administration. It is active against most Gram-positive and Gram-negative bacteria, but inactive against non-fermenting Gram-negative rods including Pseudomonas aeruginosa. nalidixic acid Antibiotic Nalidixic acid is a quinolone derivative of naphthyridine active against many enterobacteria, but ineffective against Ps aeruginosa, Gram-positive bacteria, and anaerobes. Acquired resistance is common in nalidixic acid treatments. norfloxacin Antibiotic Norfloxacin is a 6-fluoro, 7-piperazinyl quinolone with a wide range of activity against Gram-negative bacteria. It is inactive against most anaerobes. sparfloxacin Antibiotic Sparfloxacin is a dimethylpiperazinyl difluoroquinolone that acts by inhibiting DNA gyrase. It is active against aerobic Gram-positive and Gram-negative bacteria, as well as some mycobacteria. It has moderate activity against some anaerobes. fluoroquinolone antibiotic Drug Class The fluoroquinolones are a family of synthetic broad-spectrum antibiotics that are 4-quinolone-3-carboxylates. These compounds interact with topoisomerase II (DNA gyrase) to disrupt bacterial DNA replication, damage DNA, and cause cell death. antibiotic target protection Resistance Mechanism Protection of antibiotic action target from antibiotic binding, which process will result in antibiotic resistance.